The study was conducted on 500 people living with HIV as it was found that they were not at high risk of developing a serious form of SARS-CoV-2 infection. Of these, one-third received long-term treatment with protease inhibitors as part of their antiviral therapy.
For one year, 12% of participants taking protease inhibitors and 22% of those not receiving these drugs were diagnosed with coronavirus. 4 patients in the last group were hospitalized with COVID-19.
The results showed that people who were given protease inhibitors had a 70% lower risk of COVID-10 infection than those who did not receive treatment, according to data presented at the European Congress of Clinical Microbiology and Infectious Diseases.
“Protease inhibitors have been used for a long time, have a good safety profile and are generally well tolerated. They can prevent the spread of infections and mutations in future variants,” said Dr. Steve Nguala of Villeneuve Hospital. Saint-Georges.
–
